Role of Genetics

The genetic mutation behind Duchenne.

Understanding the cause of Duchenne begins with understanding the role of proteins and genes in how our bodies function.


Proteins are necessary for many important functions in the body, such as digesting our food, growing our bones, or—in the case of the protein called dystrophin—helping our muscles work properly.

Genes are made up of segments, called “exons,” that tell our cells which proteins to make. The dystrophin gene is made up of 79 exons that, when linked together, form the instructions for making dystrophin.

Image
Nicholas

Meet Nicholas, age 17
Amenable to exon 53 skipping


What is a genetic mutation?

A mutation is a change in a person’s DNA. Mutations range in size from a small (a single rung on a ladder) to a large segment of DNA. Every mutation causes a different effect on our bodies. A mutation on the dystrophin gene means dystrophin is not produced—resulting in Duchenne.

3 common types of mutations.

Large deletions

One or more exons are missing

72%

of people with Duchenne

8%

About 8% of people diagnosed with Duchenne have the genetic mutation that is amenable to VYONDYS 53. Learn what this means.

Large duplications

One or more exons are duplicated

7%

of people with Duchenne
(Not treatable with VYONDYS 53)

Other changes

Small deletions or interruptions in the instructions

20%

of people with Duchenne
(Not treatable with VYONDYS 53)

VYONDYS 53 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 53. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

The importance of genetic testing.

While there is presently no cure for Duchenne, advances in research offer hope. Genetic testing can now pinpoint the specific exons that are missing from the dystrophin gene. That’s why it’s so important for every child living with Duchenne to have a current genetic test—and for parents to understand the results.
 

Your child has a confirmed diagnosis of Duchenne. Have they had a genetic test?
 

 

No.




 

 

Now is the time to talk to your childs doctor about testing.
Learn about genetic testing.

 

Yes,

a recent test, but I’m not sure about the results.

 


Ask your child’s doctor to review the test to see if the genetic mutation is identified. Learn how to read the test results yourself.

 

Yes,

but it was several years ago.
 

 


Test methods have improved in recent years. Talk to your doctor about a retest to identify the mutation.

 

 

How is a genetic test performed? Getting a genetic test is usually as simple as providing a blood or saliva sample.

1.

To confirm a Duchenne diagnosis

2.

To identify the genetic mutation and explore possible therapy options

3.

To facilitate potential clinical trial participation

4.

To assist with family planning

 

 

Wondering what to expect?

Get insights into the Duchenne diagnostic process.

 

Explore our Doctor Discussion Guide

Our helpful guide has information on what to ask during an appointment.

 

 

Image
Desktop star

Sign up to get updates
from Sarepta.  

Related FAQs

How will I know if my child can be treated with VYONDYS 53?

A doctor will need to interpret the test results to consider appropriate treatment options. Learn more about deletions.

Is the treatment effective?

Weekly infusions of VYONDYS 53 helped the body make a shorter form of the dystrophin protein in some boys. View the results from clinical studies.

VYONDYS 53 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 53.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

 

 

WHAT IS VYONDYS 53 (golodirsen)?

VYONDYS 53 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 53.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Read More

IMPORTANT RISK INFORMATION

Allergic reactions, including rash, fever, itching, hives, and inflammation and/or peeling of the skin have occurred in patients who were treated with VYONDYS 53. Seek immediate medical care if signs and symptoms of allergic reactions occur.

Damage to the kidneys was seen in animals who received golodirsen. Although damage to the kidneys was not seen in clinical studies with VYONDYS 53, potentially fatal kidney damage has occurred with other drugs that work in a similar way. Your doctor may recommend urine and blood testing before starting treatment followed by urine testing every month and a blood test every 3 months to monitor your kidneys.

IMPORTANT RISK INFORMATION

Allergic reactions, including rash, fever, itching, hives, and inflammation and/or peeling of the skin have occurred in patients who were treated with VYONDYS 53.  Seek immediate medical care if signs and symptoms of allergic reactions occur.

Damage to the kidneys was seen in animals who received golodirsen. Although damage to the kidneys was not seen in clinical studies with VYONDYS 53, potentially fatal kidney damage has occurred with other drugs that work in a similar way. Your doctor may recommend urine and blood testing before starting treatment followed by urine testing every month and a blood test every 3 months to monitor your kidneys.

Adverse reactions that have occurred in at least 20% of patients treated with VYONDYS 53 and more often than in patients who received an inactive intravenous (IV) infusion were headache (41%, 10%), fever (41%, 14%), fall (29%, 19%), pain in the abdomen (27%, 10%), infection of the nose and throat (27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).

Other adverse reactions that occurred in greater than 5% of patients treated with VYONDYS 53 and more often than in patients who received an inactive IV infusion were pain at the IV site, back pain, pain, diarrhea, dizziness, stretch or tear in a ligament, bruising, flu, pain in the mouth and throat, stuffy or runny nose, scrapes or scratches of the skin, ear infection, seasonal allergy, fast heartbeat, reactions related to the IV catheter site, constipation, and broken bones.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see the full Prescribing Information for VYONDYS 53 (golodirsen).